

2023

Public engagement highlights

Annual overview of the involvement of patients and healthcare professionals (HCP) in the work of EMA



In 2023 EMA launched an initiative to develop a reflection paper on [patient experience data \(PED\)](#), aiming for public consultation in 2024. The [Big Data workplan](#), updated in 2023, includes reinforced collaboration with patient and healthcare professional representatives and close links to the PED initiative. June 2023 marked the 10th anniversary of the Healthcare Professionals' Working Party (HCPWP). The [CHMP early dialogue methodology](#) was extended to include non-orphan medicines and healthcare professional organisations. For more information, see the [2022-23 Stakeholder Engagement report](#).

Stakeholder involvement in medicine-related activities

Patient contribution to EMA's work

Patient membership numbers	39
EMA Management Board	2
Scientific committees	15
Patients' and Consumers' Working Party	22
Active patient experts	144
Patients/consumers eligible organisations	43

HCP contribution to EMA's work

HCP membership numbers	36
EMA Management Board	2
Scientific committees	12
HCP Working Party	22
Active HCP experts	127
HCP eligible organisations	40

Working party meetings

March

EMA working party reorganisation, Medical devices, Clinical trials, Biosimilars and interchangeability, EMA policy on multilingualism

[Access meeting documents](#)

June

Pharmacovigilance, Clinical trials, DARWIN EU, Electronic product information, Medicine shortages, Nitrosamines

[Access meeting documents](#)

September

Involvement of patient and HCP representatives in EMA groups, Updates on crisis preparedness, Big data, Medicine shortages, Clinical trials, EMA communications

[Access meeting documents](#)

November

Availability and accessibility of medicines, EMA data-related initiatives and digitalisation, Regulatory science and innovation, Communications, Members' voice

[Access meeting documents](#)

Key events

ACT EU multistakeholder platform kick-off meeting and workshop on ICH E6 R3

In June 2023, the multistakeholder platform and advisory group were established to advise on priorities and contribute to ACT EU deliverables. The workshop identified the need for a dedicated action on clinical trials in public health emergencies. In July, an ACT EU workshop focused on revising ICH E6(R3) Good Clinical Practice guidance. The PCWP and HCPWP submitted a joint contribution to the ICH public consultation, marking the culmination of years of collaboration.

[View MSP kick-off event summary](#) [View ICH E6 R3 event summary](#)

Workshop on long-COVID


A workshop with representatives from academia, industry, regulators, healthcare professionals, and patients discussed designing clinical trials to support treatment and prevention of long COVID and post-acute sequelae condition.

[View event summary](#)

Patient engagement in medicine-specific activities

Patients in scientific advice procedures	43
Patients in scientific advisory groups	31
Patients in committee consultations	17
Responses to CHMP early contact procedures	32
Review of documents by patients	50

Queries by stakeholder



Total number queries: **1524**
Overall satisfaction: **76%**

Common topics:
COVID-19, Availability, DNA-contamination, Paediatrics